The aims of the study were to determine the in vitro activity of doripenem, a new
carbapenem, against a large number of bacterial pathogens and to propose zone diameter …

The Comparative Activity of Carbapenems Testing (COMPACT) Study was designed to
determine the in vitro potency of doripenem compared with imipenem and meropenem …

Objective: To assess the in vitro efficacy of doripenem against Pseudomonas aeruginosa
and Acinetobacter baumannii using Epsilometer strips. Study Design: Cross-sectional study …

Objectives: To determine the spectrum of activity of doripenem and to propose tentative MIC
and disc diffusion breakpoints. Methods: The in vitro susceptibilities of 2137 bacterial …

Objectives Doripenem is a new carbapenem recently introduced into Europe. The
COMParative Activity of Carbapenem Testing (COMPACT) study compared the susceptibility …

Doripenem, a parenteral, broad-spectrum antibacterial agent of the carbapenem family, is
indicated as empirical therapy in serious bacterial infections in adults. Doripenem is …

Doripenem (Doribax®, Ortho-McNeal Pharmaceuticals) is the latest carbapenem analog to
be licensed in the European Union (EU) and United States, joining imipenem (1985) …

Doripenem is a broad-spectrum parenteral carbapenem recently approved in the United
States for treatment of complicated urinary tract and intra-abdominal infections. Although …

The in vitro activity of doripenem against prevalent nonfermentative Gram-negative bacilli
and Aeromonas spp. was evaluated. The collection comprised 15 236 nonduplicate clinical …

Background Doripenem is the most recently introduced antimicrobial agent of the
carbapenem class. It is a valuable therapeutic option in the context of increasing …